Search across 105,000+ research abstracts, articles, substances, health topics, keywords, and actions.
Found 11 results for "urolithin"
Conventional medicine treats menopause as an estrogen-deficiency disease to be managed and overridden. But
Sayer Ji
16 min
Double Nobel laureate Linus Pauling argued that vitamin C deficiency -- not cholesterol -- is the root
Sayer Ji
7 min
Ever since chemotherapy and radiation became the 'standard of care,' oncology has been in the
Sayer Ji
5 min
Looking for a simple antiaging tool to boost your physical, psychological and sexual health? This
GMI Research Group
5 min
Originally published on www.deannaminich.com Everyone is affected by environmental fluctuations, whether yearly with the changing seasons or daily with cycles of lightness and darkness. Monthly chan...
deannaminich
11 minIn recent years, CeO nanoparticles are promising biomaterials due to their excellent biocompatibility and antioxidant properties. This study utilizes a methacrylated gelatin (GelMA) hydrogel platform to construct a dual-functional composite material, CeUA@GelMA, by co-loading CeO nanoparticles with urolithin A (UA). This material possesses both reactive oxygen species (ROS) scavenging and mitophagy activation capabilities, aiming to overcome the bottleneck in cartilage regeneration by regulating mitochondrial homeostasis. experiments confirmed that this material significantly reduces ROS levels within BMSCs under oxidative stress, maintains mitochondrial membrane potential, and promotes chondrogenic differentiation by upregulating genes such as Sox9, Col II, and ACAN. studies demonstrated that the CeUA@GelMA group achieved hyaline-like cartilage regeneration 8 weeks post-operation. The surface roughness of the newly formed cartilage was comparable to that of natural cartilage, with collagen and glycosaminoglycan density approaching normal cartilage levels. In summary, this research offers an innovative strategy and hydrogel material for cartilage tissue engineering through the regulation of mitochondrial homeostasis.
Sleep loss drives metabolic and immune dysfunction, yet the epigenetic links to inflammation remain poorly defined. Using larval zebrafish with a continuous-swim paradigm, we demonstrate that acute sleep deprivation (SD) induces sleep fragmentation, systemic oxidative stress, and sustained neutrophilic inflammation─phenotypes associated with elevated histone H3K18 lactylation (H3K18la), an epigenetic modification from glycolytic lactate. Critically, gut microbiota metabolite Urolithin A (UA) exerts potent protection: it downregulates ROS-generating and glycolysis-related genes and reduces intracellular lactate and histone lactylation, collectively disrupting the pathogenic ROS-H3K18la feedback loop. Mechanistically, UA reduces aberrant H3K18la deposition at the and promoters to suppress transcription. Functional assays confirm that UA rescues SD-impaired inflammation resolution, reduces excessive neutrophil recruitment/retention at injury sites, and restores antioxidant homeostasis. These findings identify UA as a multitarget modulator that mitigates SD-associated inflammation via the ROS-H3K18la-inflammation axis, highlighting its translational potential for sleep loss-related immune/metabolic disorders.
There were some errors in the original publication [...].
The decline in productivity and increased immune stress associated with hepatic oxidative stress in aging laying hens limit the efficiency of egg production. Urolithin A (UA), a natural metabolite, has been shown to activate the Nrf2 antioxidant pathway in mammals; however, its effects and underlying mechanisms in laying hens remain unclear. This study aimed to systematically evaluate the dose-response effects of dietary UA on the health and production performance of laying hens, with an emphasis on its role in activating the Nrf2 pathway. Fifty (45-week-old) Roman Pink laying hens were randomly assigned to one of five dietary treatments: a basal diet supplemented with 0, 50, 200, 400, or 800 mg/kg UA for 6 weeks. The production performance, organ indices, serum and liver lipid profiles, antioxidant status, immune markers, liver histology, and Nrf2 pathway-related mRNA and protein expression were assessed. An in vitro model of primary chicken hepatocytes was also used to validate the direct effects of UA. Compared with the control group (0 mg/kg UA), 200 mg/kg UA supplementation showed significantly improved the laying rate and egg weight, reduced the feed-to-egg ratio, and lowered the serum total cholesterol and triglyceride levels (P < 0.05). This optimal dose also enhanced the total antioxidant capacity and superoxide dismutase and glutathione peroxidase activities in both the serum and liver, decreased the malondialdehyde levels, and increased the immunoglobulin (IgY and IgA) concentrations (P < 0.05). UA at 400 and 800 mg/kg doses did not enhance egg laying (P > 0.05), but significantly reduced liver and abdominal fat indices (P < 0.05). All UA doses lowered hepatic TC content (P < 0.05), but only the higher doses (400 and 800 mg/kg) significantly decreased liver VLDL-C levels (P < 0.05). At the molecular level, 200 mg/kg UA significantly upregulated the mRNA and protein expression of Nrf2 and its key downstream targets in the liver (P < 0.05). These effects were corroborated in vitro, where 5 μmol/L UA significantly promoted hepatocyte viability and upregulated Nrf2 and downstream mRNA expression (P < 0.05). This study is the first to provide systematic evidence that supplementing with 200 mg/kg UA may enhance late-phase laying performance by boosting antioxidant capacity, regulating lipid metabolism, and improving immune function, likely through activation of the hepatic Nrf2 pathway, suggesting its potential as a natural feed additive for sustained peak production.
Over the past decade, research on urolithins has expanded significantly due to their role as mediators between polyphenol-rich diets and human health. Understanding the relationships between ellagitannin intake, gut microbiota composition, and urolithin production is essential for evaluating their biological effects and nutraceutical potential. The primary objective of this review is to critically summarise current knowledge on urolithins, bioactive metabolites derived from ellagitannins in plant-based foods, with a focus on their biosynthesis, bioavailability, protein interactions, and potential therapeutic applications. A comprehensive literature search was conducted using PubMed, Scopus, and Google Scholar to identify studies on urolithin biosynthesis, absorption, transport mechanisms, protein binding, and incorporation into extracellular vesicles. Relevant articles were critically analysed to synthesise current evidence and highlight emerging concepts. Key findings indicate that after absorption, urolithins bind to serum albumin, which facilitates their transport to target tissues, exerting anti-inflammatory and antioxidant actions. Recent evidence also shows that urolithins can be packaged into extracellular vesicles, suggesting novel mechanisms for intracellular transport and potential therapeutic applications. This review highlights gaps in current knowledge and proposes directions for future research to optimise their therapeutic potential.
Subscribe to our informative Newsletter & Receive
Cancer Fighting Foods Ebook
Our newsletter serves 500,000 with essential news, research & healthy tips, daily.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of GreenMedInfo or its staff.
